source
- FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolioRegeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
- Isomorphic Labs partners with Merck on AI-driven oncology drug discovery after $5 billion funding roundIsomorphic Labs announced a new collaboration with Merck & Co., adding the pharma giant to its AI drug discovery partners. The agreement follows Isomorphic's recent $5 billion financing and will f…